The Effect of Oxytocin on Gastric Emptying

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bodil Ohlsson, Skane University Hospital
ClinicalTrials.gov Identifier:
NCT01152047
First received: June 23, 2010
Last updated: April 6, 2015
Last verified: April 2015
  Purpose

The investigators have seen that oxytocin lowers satiety in healthy subjects. Patients with dyspepsia suffers from decreased accommodation and increased satiety postprandially. The investigators now want to examine whether oxytocin may diminish symptoms in these patients.


Condition Intervention
Dyspepsia
Lack of Satiety
Drug: oxytocin

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
Official Title: The Effect of Oxytocin on Satiety in Patients With Dyspepsia

Resource links provided by NLM:


Further study details as provided by Skane University Hospital:

Primary Outcome Measures:
  • Satiety [ Time Frame: 2 h ] [ Designated as safety issue: No ]
    The investigator want to examine whether oxytocin leads to lower satiety scores after intake of the same volume of nutrient


Other Outcome Measures:
  • To see if oxytocin lowers satiety [ Time Frame: 2h ] [ Designated as safety issue: No ]
    To perform a drinking satiety test twice. Once with oxytocin and once with saline. Then examine whether oxytocin decreases satiety compared to saline


Enrollment: 14
Study Start Date: May 2010
Study Completion Date: April 2015
Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: oxytocin, satiety
Oxytocin is given as infusion to examine if this decreases satiety compared to saline during a drinking test
Drug: oxytocin
40mU/min as infusion of oxytocin
Other Name: syntocinon

Detailed Description:

Patients will come twice for a slow satiety drinking test. Once they will get saline infusion and once oxytocin 40 mU/min. At the same time they register satiety on a VAS scale.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Dyspepsia

Exclusion Criteria:

  • Age > 65 years
  • Cardiac disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01152047

Locations
Sweden
Skåne University Hospital
Malmö, Sweden, 205 02
Sponsors and Collaborators
Skane University Hospital
Investigators
Principal Investigator: Bodil Ohlsson, professor Divsion of Internal Medicine
  More Information

No publications provided

Responsible Party: Bodil Ohlsson, Department of Clinical Sciences, Division of Internal Medicine, Skane University Hospital
ClinicalTrials.gov Identifier: NCT01152047     History of Changes
Other Study ID Numbers: 2009/502, 2009/502
Study First Received: June 23, 2010
Last Updated: April 6, 2015
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by Skane University Hospital:
oxytocin
satiety
dyspepsia

Additional relevant MeSH terms:
Dyspepsia
Signs and Symptoms
Signs and Symptoms, Digestive
Oxytocin
Oxytocics
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 30, 2015